| Date | Title | Description |
| 05.03.2026 | Precision BioSciences Secures $7.5M Milestone for MS Therapy Progress | Precision BioSciences, a pioneering gene editing company, achieved a significant $7.5 million clinical milestone. This crucial payment stems from its partnership with TG Therapeutics. It recognizes impressive progress for Azer-Cel, a ground... |
| 03.03.2026 | Precision BioSciences: $7.5 Million Milestone From TG Therapeutics For Azer-Cel Clinical Progress In Multiple Sclerosis | Precision BioSciences, a clinical-stage gene editing company leveraging its proprietary ARCUS platform, announced it has received $7.5 million in proceeds from TG Therapeutics following the achievement of a clinical milestone tied to azerca... |
| 01.07.2025 | Australia’s Resource Earnings Face a Rocky Road Ahead | Australia’s resource sector is bracing for a storm. A recent government report paints a bleak picture for the country’s mining and energy export earnings. The forecast is clear: trade risks loom large, and commodity prices are on a downward... |
| 30.06.2025 |
Cramer’s Lightning Round: TG Therapeutics is a buy | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Rio Tinto: “Big yield. I believe in the min... |
| 08.03.2024 | TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting | - |
| 04.01.2022 | TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million | NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility... |
| 04.01.2022 | TG Therapeutics Expands Term Loan Facility with Hercules Capital to $200 Million | TG Therapeutics, Inc. announced that its existing term loan facility agreement with Hercules Capital, Inc. has been amended to increase the size of the facility to $200 million, with $70 million funded at closing. Under the terms of the ame... |
| 04.01.2022 | TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million | NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility... |
| 30.11.2021 | FDA raises concerns over TG Therapeutics' survival data, plans to convene ODAC | TG Therapeutics took a hit Tuesday morning after announcing the FDA will convene an adcomm ahead of the biotech’s upcoming PDUFA date for a blood cancer combo therapy, throwing a potential decision into limbo.
Though... |
| 04.11.2021 | TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - Form 8-K | TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET
New York, NY, (November 4, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) tod... |
| 04.11.2021 | TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results | NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the rem... |
| 14.10.2021 | TG Therapeutics : Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis | New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score
Data from the ULTIMATE I & II Phase 3 trials recently s... |
| 29.09.2021 | TG Therapeutics : Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment... | The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p |
| 20.09.2021 | TG Therapeutics : Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL) | NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). Data highlights from each presentation are incl... |
| 02.08.2021 | TG Therapeutics : Provides Business Update and Reports Second Quarter 2021 Financial Results (Form 8-K) | TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
Conference call to be held today, Monday, August 2, 2021 at 8:30 AM ET
New York, NY, (August 2, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today an... |
| 02.08.2021 | TG Therapeutics : Provides Business Update and Reports Second Quarter 2021 Financial Results | NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ending June 30, 2021 and recent company developments, along with a business outlook for the remain... |
| 14.06.2021 | TG THERAPEUTICS, INC.
TG Therapeutics : Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ at the 2021 European Hematology... | NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), announced data from TG-1701, the Company's investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Company's novel glycoe... |
| 07.06.2021 | TG THERAPEUTICS, INC.
TG Therapeutics : Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ at the 2021 American Society of... | NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), announced data from TG-1701, the Company's investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Company's novel glycoe... |
| 04.06.2021 | TG THERAPEUTICS, INC.
TG Therapeutics : Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society o... | 100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19)
Triple combination of ublituximab and UKONIQ (U2) + TG-1701 cohort (n=19) resulted in 79% ORR, with 21% CR rate, including 100% ORR in patients WM, CLL, MZL, MCL,... |
| 16.04.2021 | TG Therapeutics prepares to approach regulators with MS drug; Investors bet $93M on a life sciences tools company | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 16.04.2021 | Covid-19 roundup: Biden invests $1.7B to address Covid variants; EU puts faith in Pfizer with new vaccine deals | The Biden administration said Friday that it’ll pump $1.7 billion into various programs to address Covid-19 variants as the original strain of Covid-19 makes up only about half of all US cases today.
Most of those new funds... |
| 16.04.2021 | In one of their first ever acquisitions, Relay bets $85M cash on a new AI-based screening approach | Although they’ve never been short for cash, Relay Therapeutics hasn’t been one for acquisitions in its 5-year history, focusing instead on developing its own tools to study how proteins move and advancing molecules off... |
| 16.04.2021 | Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients | Among a positively jam-packed multiple sclerosis market, Roche’s Ocrevus has managed to stand out for what the Swiss drugmaker is calling the most successful launch in its long history. But in order to press its advantag... |
| 16.04.2021 | Covid-19 roundup: Biden invests $1.7B to address Covid variants; EU puts faith in Pfizer with new vaccine deals | The CDC’s Advisory Committee on Immunization Practices punted earlier this week on deciding whether or not to recommend lifting a pause on the administration of J&J’s Covid-19 vaccine, but the committee will meet again in an emergency s... |
| 16.04.2021 | Novavax CFO Greg Covino makes a quick exit as leadership carousel keeps turning; Kite execs fly away to a cell therapy upstart teaming up with Lyell | Greg Covino
→ If it seems like Covid-19 vaccine bridesmaid Novavax is shuttling staffers in and out, you’re not alone. This week, Greg Covino announced he’s leaving the biotech after holding the CFO job for a blink-and-you-miss-it... |
| 16.04.2021 | TG Therapeutics prepares to approach regulators with MS drug; Investors bet $93M on a life sciences tools company | Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its... |
| 16.04.2021 | TG Therapeutics prepares to approach regulators with MS drug; Investors bet $93M on a life sciences tools company | Gearing up for a battle with pharma giants, TG Therapeutics says it’s nearly ready to approach regulators with its CD20 drug for multiple sclerosis.
The biotech read out results from two Phase III trials at AAN, which show... |
| 16.04.2021 | TG THERAPEUTICS, INC.
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd... | Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions
Ublituximab was generally well tolerated, with no unexpected safety signals
BLA submission targeted in Q3 2021
Webcast to b... |
| 15.04.2021 | Abzena picks North Carolina as the home for its 6th manufacturing site, plans to add 325 jobs in Sanford | While Boston and San Francisco are the unquestioned leading biotech hubs in the US, drugmakers — particularly contract manufacturers — are looking elsewhere for cheaper real estate and untapped potential. Now, a San ... |
| 10.12.2020 | Angling for a spot among the giants, TG Therapeutics touts PhIII MS data for CD20 drug | While the pharma giants duke it out in multiple sclerosis, a biotech is taking a crack at the shaking up the market.
TG Therapeutics says they’ll be headed to the FDA in mid-2021 armed with strong late-stage data on ublituxi... |
| 10.11.2020 | TG THERAPEUTICS, INC.
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results | NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Michael S. Weiss, the Company's Executive... |
| 10.11.2020 | TG THERAPEUTICS, INC.
TG Therapeutics : Provides Business Update and Reports Third Quarter 2020 Financial Results | NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Michael S. Weiss, the Company's Executive... |
| 11.10.2020 | TG Therapeutics : Provides Business Update and Reports Third Quarter 2020 Financial Results | NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Michael S. Weiss, the Company's Executive... |
| 22.01.2019 | TG Therapeutics' shares jump as umbralisib wins FDA's breakthrough status | About a month after the publication of encouraging results from an early-stage study evaluating J&J’s Imbruvica in combination with its experimental drug umbralisib, TG Therapeutics on Tuesday said the drug ... |
| 04.07.2018 | Novimmune to receive up to $185M milestone payments | |
| 06.03.2017 | TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK | Michael S. Weiss
Shares of TG Therapeutics $TGTX rocketed up 64% this morning after the New York-based biotech reported that its lead cancer drug scored a win in Phase III. And now the biotech plans to pursue an accelerated a... |
| 06.05.2013 | Former Keryx Exec’s Mission: Turn TG Into the Next Pharmacyclics | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Seven years running a publicly-traded biotech are likely to give anyone a sense of the manic nature and the volatile ups and downs of drug development. And Mike Weiss, who hea... |
| - | Here are the 15 highest-paid CEOs in biopharma, bringing in paychecks of at least $25 million in 2021 — with 2 making over $100 million | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider got exclusive data on the highest-paid CEOs in the pharma and biotech industries in 2021.
The research firm MyLogIQ identified 15 C... |
| - | Stocks making the biggest moves midday: Netflix, Cal-Maine Foods, Southwest and more | Check out the companies making headlines in midday trading.
Netflix — The streaming giant gained 5.1% following a double upgrade to buy from sell by CFRA. The firm said it would be difficult for competitors to catch up with the company.
Cal... |
